Cargando…

Procalcitonin Evaluation of Antibiotic Use in COVID-19 Hospitalised Patients (PEACH): Protocol for a Retrospective Observational Study

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel virus responsible for the coronavirus disease 2019 (COVID-19) pandemic. Although COVID-19 is a viral illness, many patients admitted to hospital are prescribed antibiotics, based on concerns that COVID-19 patients may experience...

Descripción completa

Detalles Bibliográficos
Autores principales: Euden, Joanne, Pallmann, Philip, Grozeva, Detelina, Albur, Mahableshwar, Bond, Stuart E., Brookes-Howell, Lucy, Dark, Paul, Hellyer, Thomas, Hopkins, Susan, Howard, Philip, Llewelyn, Martin J., Maboshe, Wakunyambo, McCullagh, Iain J., Ogden, Margaret, Parsons, Helena, Partridge, David, Powell, Neil, Shaw, Dominick, Shinkins, Bethany, Szakmany, Tamas, Todd, Stacy, Thomas-Jones, Emma, West, Robert M., Carrol, Enitan D., Sandoe, Jonathan A. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786133/
https://www.ncbi.nlm.nih.gov/pubmed/36548137
http://dx.doi.org/10.3390/mps5060095
_version_ 1784858218239885312
author Euden, Joanne
Pallmann, Philip
Grozeva, Detelina
Albur, Mahableshwar
Bond, Stuart E.
Brookes-Howell, Lucy
Dark, Paul
Hellyer, Thomas
Hopkins, Susan
Howard, Philip
Llewelyn, Martin J.
Maboshe, Wakunyambo
McCullagh, Iain J.
Ogden, Margaret
Parsons, Helena
Partridge, David
Powell, Neil
Shaw, Dominick
Shinkins, Bethany
Szakmany, Tamas
Todd, Stacy
Thomas-Jones, Emma
West, Robert M.
Carrol, Enitan D.
Sandoe, Jonathan A. T.
author_facet Euden, Joanne
Pallmann, Philip
Grozeva, Detelina
Albur, Mahableshwar
Bond, Stuart E.
Brookes-Howell, Lucy
Dark, Paul
Hellyer, Thomas
Hopkins, Susan
Howard, Philip
Llewelyn, Martin J.
Maboshe, Wakunyambo
McCullagh, Iain J.
Ogden, Margaret
Parsons, Helena
Partridge, David
Powell, Neil
Shaw, Dominick
Shinkins, Bethany
Szakmany, Tamas
Todd, Stacy
Thomas-Jones, Emma
West, Robert M.
Carrol, Enitan D.
Sandoe, Jonathan A. T.
author_sort Euden, Joanne
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel virus responsible for the coronavirus disease 2019 (COVID-19) pandemic. Although COVID-19 is a viral illness, many patients admitted to hospital are prescribed antibiotics, based on concerns that COVID-19 patients may experience secondary bacterial infections, and the assumption that they may respond well to antibiotic therapy. This has led to an increase in antibiotic use for some hospitalised patients at a time when accumulating antibiotic resistance is a major global threat to health. Procalcitonin (PCT) is an inflammatory marker measured in blood samples and widely recommended to help diagnose bacterial infections and guide antibiotic treatment. The PEACH study will compare patient outcomes from English and Welsh hospitals that used PCT testing during the first wave of the COVID-19 pandemic with those from hospitals not using PCT. It will help to determine whether, and how, PCT testing should be used in the NHS in future waves of COVID-19 to protect patients from antibiotic overuse. PEACH is a retrospective observational cohort study using patient-level clinical data from acute hospital Trusts and Health Boards in England and Wales. The primary objective is to measure the difference in antibiotic use between COVID-19 patients who did or did not have PCT testing at the time of diagnosis. Secondary objectives include measuring differences in length of stay, mortality, intensive care unit admission, and resistant bacterial infections between these groups.
format Online
Article
Text
id pubmed-9786133
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97861332022-12-24 Procalcitonin Evaluation of Antibiotic Use in COVID-19 Hospitalised Patients (PEACH): Protocol for a Retrospective Observational Study Euden, Joanne Pallmann, Philip Grozeva, Detelina Albur, Mahableshwar Bond, Stuart E. Brookes-Howell, Lucy Dark, Paul Hellyer, Thomas Hopkins, Susan Howard, Philip Llewelyn, Martin J. Maboshe, Wakunyambo McCullagh, Iain J. Ogden, Margaret Parsons, Helena Partridge, David Powell, Neil Shaw, Dominick Shinkins, Bethany Szakmany, Tamas Todd, Stacy Thomas-Jones, Emma West, Robert M. Carrol, Enitan D. Sandoe, Jonathan A. T. Methods Protoc Protocol Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel virus responsible for the coronavirus disease 2019 (COVID-19) pandemic. Although COVID-19 is a viral illness, many patients admitted to hospital are prescribed antibiotics, based on concerns that COVID-19 patients may experience secondary bacterial infections, and the assumption that they may respond well to antibiotic therapy. This has led to an increase in antibiotic use for some hospitalised patients at a time when accumulating antibiotic resistance is a major global threat to health. Procalcitonin (PCT) is an inflammatory marker measured in blood samples and widely recommended to help diagnose bacterial infections and guide antibiotic treatment. The PEACH study will compare patient outcomes from English and Welsh hospitals that used PCT testing during the first wave of the COVID-19 pandemic with those from hospitals not using PCT. It will help to determine whether, and how, PCT testing should be used in the NHS in future waves of COVID-19 to protect patients from antibiotic overuse. PEACH is a retrospective observational cohort study using patient-level clinical data from acute hospital Trusts and Health Boards in England and Wales. The primary objective is to measure the difference in antibiotic use between COVID-19 patients who did or did not have PCT testing at the time of diagnosis. Secondary objectives include measuring differences in length of stay, mortality, intensive care unit admission, and resistant bacterial infections between these groups. MDPI 2022-11-28 /pmc/articles/PMC9786133/ /pubmed/36548137 http://dx.doi.org/10.3390/mps5060095 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Protocol
Euden, Joanne
Pallmann, Philip
Grozeva, Detelina
Albur, Mahableshwar
Bond, Stuart E.
Brookes-Howell, Lucy
Dark, Paul
Hellyer, Thomas
Hopkins, Susan
Howard, Philip
Llewelyn, Martin J.
Maboshe, Wakunyambo
McCullagh, Iain J.
Ogden, Margaret
Parsons, Helena
Partridge, David
Powell, Neil
Shaw, Dominick
Shinkins, Bethany
Szakmany, Tamas
Todd, Stacy
Thomas-Jones, Emma
West, Robert M.
Carrol, Enitan D.
Sandoe, Jonathan A. T.
Procalcitonin Evaluation of Antibiotic Use in COVID-19 Hospitalised Patients (PEACH): Protocol for a Retrospective Observational Study
title Procalcitonin Evaluation of Antibiotic Use in COVID-19 Hospitalised Patients (PEACH): Protocol for a Retrospective Observational Study
title_full Procalcitonin Evaluation of Antibiotic Use in COVID-19 Hospitalised Patients (PEACH): Protocol for a Retrospective Observational Study
title_fullStr Procalcitonin Evaluation of Antibiotic Use in COVID-19 Hospitalised Patients (PEACH): Protocol for a Retrospective Observational Study
title_full_unstemmed Procalcitonin Evaluation of Antibiotic Use in COVID-19 Hospitalised Patients (PEACH): Protocol for a Retrospective Observational Study
title_short Procalcitonin Evaluation of Antibiotic Use in COVID-19 Hospitalised Patients (PEACH): Protocol for a Retrospective Observational Study
title_sort procalcitonin evaluation of antibiotic use in covid-19 hospitalised patients (peach): protocol for a retrospective observational study
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786133/
https://www.ncbi.nlm.nih.gov/pubmed/36548137
http://dx.doi.org/10.3390/mps5060095
work_keys_str_mv AT eudenjoanne procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT pallmannphilip procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT grozevadetelina procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT alburmahableshwar procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT bondstuarte procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT brookeshowelllucy procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT darkpaul procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT hellyerthomas procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT hopkinssusan procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT howardphilip procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT llewelynmartinj procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT maboshewakunyambo procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT mccullaghiainj procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT ogdenmargaret procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT parsonshelena procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT partridgedavid procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT powellneil procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT shawdominick procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT shinkinsbethany procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT szakmanytamas procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT toddstacy procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT thomasjonesemma procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT westrobertm procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT carrolenitand procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy
AT sandoejonathanat procalcitoninevaluationofantibioticuseincovid19hospitalisedpatientspeachprotocolforaretrospectiveobservationalstudy